Reply: Potential role of Janus kinase inhibitors in COVID-19
M Napolitano, G Fabbrocini, C Patruno - Journal of the American Academy …, 2020 - jaad.org
To the Editor: We read with interest the letter of Peterson et al 1 about the use of Janus
kinase (JAK) inhibitors in the time of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). The authors reported that discontinuation of JAK inhibitors in the setting of
the initial infection, such as with SARS-CoV-2, may be beneficial given the role of JAK-signal
transducer and activator of transcription (STAT) e dependent type I (/) and type II ()
interferons in antiviral immunity. However, data in the literature regarding the possible use of …
kinase (JAK) inhibitors in the time of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). The authors reported that discontinuation of JAK inhibitors in the setting of
the initial infection, such as with SARS-CoV-2, may be beneficial given the role of JAK-signal
transducer and activator of transcription (STAT) e dependent type I (/) and type II ()
interferons in antiviral immunity. However, data in the literature regarding the possible use of …